CDTi Advanced Materials announced the expected effective date of its 1-for-5 reverse stock split. Stockholders granted the board of directors discretionary authority to effect the reverse split at the company's annual meeting of stockholders held on August 24, 2018. CDTi anticipates the reverse split to be effective after the close of trading on NASDAQ on Friday, September 21, 2018, and for the common stock to continue trading on NASDAQ under the trading symbol "CDTI" under new CUSIP number 12514V204 on a split-adjusted basis commencing at the open of trading on Monday, September 24, 2018. The reverse split will reduce the number of outstanding shares of CDTi common stock from approximately 20 million shares to approximately 4 million shares. Correspondingly, the trading price of CDTi common stock is expected to proportionately increase immediately following the Effective Date. The company will not issue any fractional shares resulting from the reverse split. Instead, any stockholder who would otherwise be entitled to less than one full share of CDTi common stock will receive a cash payment for such fractional share at a rate equal to the average of the closing prices per share of CDTi common stock on NASDAQ over the five trading days immediately preceding the Effective Date.

Duke Energy crews today focused on the remaining 26,000 customers without power as of 4:30 p.m., after restoring nearly 1.8M outages in North Carolina and South Carolina during the past week in the aftermath of Hurricane Florence. Duke Energy expects to restore power to 99% of customers whose properties are able to receive power by Sunday at 11:45 p.m.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from a Phase 3 clinical study of the investigational product esketamine nasal spray in patients with treatment-resistant depression. Janssen researchers presented these results at the Ninth Biennial Conference of the International Society for Affective Disorders (ISAD) and the Houston Mood Disorders Conference, taking place September 20-22, 2018 in Houston, TX. This clinical trial was a randomized, double-blind study of two fixed doses of esketamine, 56 mg and 84 mg. The study did not demonstrate statistical significance for the primary endpoint, change in a depression severity rating scale score from baseline to four weeks, for esketamine 84 mg plus oral antidepressant compared to oral antidepressant plus placebo. Therefore, based on the prespecified analysis plan, the esketamine 56 mg plus oral antidepressant group could not be formally evaluated in this study. Importantly, results of analyses of the primary endpoint and key secondary endpoints numerically favored both esketamine plus oral antidepressant treatment groups over the oral antidepressant plus placebo group.

Chubb CEO Evan Greenberg disclosed in a filing that he had sold 61.4K shares of company stock on September 19. The total transaction value was about $8.6M.

According to a regulatory filing, on September 17, 2018, vTv Therapeutics Inc. received a written response from the FDA to its Type C Meeting Request seeking development guidance for azeliragon. In the response, the FDA advised that the efficacy of azeliragon should be demonstrated in at least two adequate and well-controlled trials, unless under the exceptional circumstances in which a single trial might suffice as set forth in the FDA's guidance document entitled "Providing Clinical Effectiveness for Human Drug and Biological Products." The company continues to assess all options for the continued development of azeliragon.

Armistice Capital reports 5.3% passive stake in Voyager Therapeutics

The company announced that its Board of Directors has authorized a new stock repurchase program, which will commence subsequent to the expiration of the previously announced company stock repurchase program that is due to expire on October 26, 2018. Under the newly authorized stock repurchase program, the company may repurchase up to $250M of its common stock over a 24 month period, commencing October 27, 2018.

Harris Corp has been awarded a maximum $255,421,604 fixed-price, requirements contract for B-52 and C-130 Special Operation Forces aircraft parts. This is a seven-year contract with no option periods. This was a sole-source acquisition using justification 10 U.S. Code 2304(c)(1), as stated in Federal Acquisition Regulation 6.302-1. Location of performance is New Jersey with a May 24, 2026, performance completion date.

FJ Capital Management reports 5.7% passive stake in Pacific Mercantile Bancorp

TDM Asset Management reports 9.1% passive stake in DAVIDsTEA

The New York Times Company (NYT) announced today that Aman Bhutani, President of the Brand Expedia Group (EXPE) at Expedia Group, Inc., has been appointed to its Board of Directors. In his present role at Expedia, which he has held since 2015, Mr. Bhutani runs all global business operations of the Brand Expedia Group including the Expedia brand globally and a set of regional brands including Travelocity, Orbitz, Cheaptickets, eBookers and Wotif. Prior to this role, he was Brand Expedia Group's chief technology officer and senior vice president of worldwide engineering, where he was well-known for having established a data-driven culture, based in the scientific method, among the group's global technology team. He's an eight year veteran of Expedia Group, Inc.